|
Vazquez C, Garcia-Vazquez E, Carrilero B, Muro M, Sanchez-Guerrero I, Gonzalez Lopez R, Franco F, Segovia M. Anticipating the side effects of benznidazole: HLA-B*35 and patch test. Enferm Infecc Microbiol Clin (Engl Ed). 2024 Oct;42(8):430-434. doi: 10.1016/j.eimce.2024.04.011. Epub 2024 Jun 19. PubMed PMID: 38902151.
AÑO: 2024
|
38902151
|
Gomez I, Egui A, Palacios G, Carrilero B, Benitez C, Simon M, Segovia M, Carmelo E, Lopez MC, Thomas MC. The expression of immune response genes in patients with chronic Chagas disease is shifted toward the levels observed in healthy subjects as a result of treatment with Benznidazole. Front Cell Infect Microbiol. 2024 Jul 23;14:1439714. doi: 10.3389/fcimb.2024.1439714. eCollection 2024. PubMed PMID: 39119291; PubMed Central PMCID: PMC11307780.
AÑO: 2024; IF: 4.6
|
|
Vazquez C, Garcia-Vazquez E, Carrilero B, Simon M, Franco F, Iborra MA, Gil-Gallardo LJ, Segovia M. Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole. Rev Soc Bras Med Trop. 2023 Jan 23;56:e0384-2022. doi: 10.1590/0037-8682-0384-2022. eCollection 2023. PubMed PMID: 36700605; PubMed Central PMCID: PMC9870279.
AÑO: 2023; IF: 1.8
|
|
Gomez I, Lopez MC, Egui A, Palacios G, Carrilero B, Benitez C, Simon M, Segovia M, Carmelo E, Thomas MC. Differential expression profile of genes involved in the immune response associated to progression of chronic Chagas disease. PLoS Negl Trop Dis. 2023 Jul 13;17(7):e0011474. doi: 10.1371/journal.pntd.0011474. eCollection 2023 Jul. PubMed PMID: 37440604; PubMed Central PMCID: PMC10368263.
AÑO: 2023; IF: 3.4
|
|
Perez-Anton E, Egui A, Thomas MC, Carrilero B, Simon M, Lopez-Ruz MA, Segovia M, Lopez MC. A proportion of CD4+ T cells from patients with chronic Chagas disease undergo a dysfunctional process, which is partially reversed by benznidazole treatment. PLoS Negl Trop Dis. 2021 Feb 4;15(2):e0009059. doi: 10.1371/journal.pntd.0009059. eCollection 2021 Feb. PubMed PMID: 33539379; PubMed Central PMCID: PMC7888659.
AÑO: 2021; IF: 4.781
|